BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 3276544)

  • 21. Characterization of late and early hematopoietic progenitor/stem cell sensitivity to mafosfamide.
    Douay L; Giarratana MC; Labopin M; Bardinet D; Bouchet S; Gorin NC
    Bone Marrow Transplant; 1995 May; 15(5):769-75. PubMed ID: 7670404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunological and pharmacological removal of small cell lung cancer cells from bone marrow autografts.
    Humblet Y; Feyens AM; Sekhavat M; Agaliotis D; Canon JL; Symann ML
    Cancer Res; 1989 Sep; 49(18):5058-61. PubMed ID: 2548708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of lymphocyte subsets after autologous bone marrow transplantation with marrow treated by ASTA Z 7557 in acute leukemia: incidence of the in vitro treatment.
    Le Blanc G; Douay L; Laporte JP; Dominh A; Deloux J; Najman A; Duhamel G; Gorin NC
    Exp Hematol; 1986 Jun; 14(5):366-71. PubMed ID: 3519264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Etoposide as an in vitro purging agent for the treatment of acute leukemias and lymphomas in conjunction with autologous bone marrow transplantation.
    Ciobanu N; Paietta E; Andreeff M; Papenhausen P; Wiernik PH
    Exp Hematol; 1986 Aug; 14(7):626-35. PubMed ID: 3525202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elimination of clonogenic tumor cells from bone marrow using methylprednisolone (MP) and etoposide VP16: an in vitro pharmacologic study.
    Miller G; Brashear T; Stone M; Fay J
    Int J Cell Cloning; 1991 Sep; 9(5):503-10. PubMed ID: 1955738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful mafosfamide purging of bone marrow from chronic myelogenous leukemia (CML) cells.
    Nieborowska-Skórska M; Skórski T; Ratajczak MZ; Szczylik C; Malaguarnera L; Calabretta B
    Folia Histochem Cytobiol; 1993; 31(4):161-7. PubMed ID: 8137996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Experimental bases of the in vitro treatment of leukemic bone marrow by a derivative of cyclophosphamide: ASTA Z 7557].
    Douay L; Gorin NC; Mary JY; Duhamel G
    C R Acad Sci III; 1985; 301(6):303-8. PubMed ID: 3928107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use and mechanism of action of AS101 in protecting bone marrow colony forming units-granulocyte-macrophage following purging with ASTA-Z 7557.
    Kalechman Y; Barkai IS; Albeck M; Horwith G; Sehagl SN; Sredni B
    Cancer Res; 1991 Oct; 51(20):5614-20. PubMed ID: 1913679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro evaluation of combination drug purging for autologous bone marrow transplantation.
    Jones RJ; Miller CB; Zehnbauer BA; Rowley SD; Colvin OM; Sensenbrenner LL
    Bone Marrow Transplant; 1990 May; 5(5):301-7. PubMed ID: 2350626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
    Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of etoposide (VP-16) cytotoxicity by verapamil or cyclosporine in multidrug-resistant human leukemic cell lines and normal bone marrow.
    Chao NJ; Aihara M; Blume KG; Sikic BI
    Exp Hematol; 1990 Dec; 18(11):1193-8. PubMed ID: 2226679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative in vitro effects of cyclophosphamide derivatives on murine bone marrow-derived stromal and hemopoietic progenitor cell classes.
    de Jong JP; Nikkels PG; Brockbank KG; Ploemacher RE; Voerman JS
    Cancer Res; 1985 Sep; 45(9):4001-5. PubMed ID: 3896474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo effects of GM-CSF and IL-3 on hematopoietic cell recovery in bone marrow and blood after autologous transplantation with mafosfamide-purged marrow in lymphoid malignancies.
    Albin N; Douay L; Fouillard L; Laporte JP; Isnard F; Lesage S; Ozsahin H; Bardinet D; Najman A; Gorin NC
    Bone Marrow Transplant; 1994 Aug; 14(2):253-9. PubMed ID: 7994241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of doxorubicin in combination with mafosfamide for in vitro elimination of myeloid and lymphoid tumor cells from human bone marrow.
    Domenech J; Georget MT; Gihana E; Colombat P; Brémond JL; Chassaigne M; Lamagnère JP; Binet C
    Bone Marrow Transplant; 1992 Feb; 9(2):101-6. PubMed ID: 1571708
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combinations of 4-hydroperoxycyclophosphamide (4-HC) and cisplatin for bone marrow purging in autologous marrow transplantation: an update.
    Peters RH; Brandon CS; Avila LA; Gale GR; Stuart RK
    Prog Clin Biol Res; 1990; 333():57-68. PubMed ID: 2309001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination.
    Lemoli RM; Gasparetto C; Scheinberg DA; Moore MA; Clarkson BD; Gulati SC
    Blood; 1991 Apr; 77(8):1829-36. PubMed ID: 2015406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Collagen gel cultures for detection of spared hematopoietic progenitors in Asta Z 7557 purged human marrows.
    Praloran V; Dobo I; Garand R; Klausman M; Naud MF; Milpied N; Harousseau JL
    Leukemia; 1990 Apr; 4(4):282-6. PubMed ID: 2366583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined ex vivo treatment with immunotoxins and mafosfamid: a novel immunochemotherapeutic approach for elimination of neoplastic T cells from autologous marrow grafts.
    Uckun FM; Stong RC; Youle RJ; Vallera DA
    J Immunol; 1985 May; 134(5):3504-15. PubMed ID: 3884712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The synthetic tetrapeptide AcSDKP protects cells that reconstitute long-term bone marrow stromal cultures from the effects of mafosfamide (Asta Z 7654).
    Genevay MC; Mormont C; Thomas F; Berthier R
    Exp Hematol; 1996 Jan; 24(1):77-81. PubMed ID: 8536796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.